カテゴリー： 世界, 医療/バイオ, Grand View Research

世界の感染症治療薬市場2023-2030：疾患種類別（HIV、肝炎、インフルエンザ、結核、マラリア、HPV）、エンドユーザー別（病院、診療所）、地域別

【英語タイトル】Infectious Disease Therapeutics Market Size, Share & Trends Analysis By Disease Type (HIV, Hepatitis, Influenza, TB, Malaria, HPV), By End-use (Hospital, Clinics), By Region, And Segment Forecasts, 2023 - 2030

Grand View Researchが出版した調査資料（GRV23NOV149）・商品コード：GRV23NOV149
・発行会社（調査会社）：Grand View Research
・発行日：2023年9月
・ページ数：81
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後3営業日）
・調査対象地域：グローバル
・産業分野：医薬品
◆販売価格オプション（消費税別）
Single UserUSD5,950 ⇒換算￥904,400見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算￥1,056,400見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算￥1,360,400見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

感染症治療薬市場の成長と動向
Grand View Research, Inc.の最新レポートによると、世界の感染症治療薬市場規模は2023年から2030年にかけて年平均成長率7.1%を記録し、2030年には1,152億米ドルに達する見込みです。同市場の主な原動力は、ヒト免疫不全ウイルス（HIV）、ヒトパピローマウイルス（HPV）、結核、肝炎の世界的な患者数の増加です。

政府機関や民間企業は、感染症の予防、診断、治療のために医療分野に多額の投資を行っており、感染症を治療するための新薬開発への投資が増加し、これらの疾患に関する意識向上のための取り組みが増加していることが、予測期間中に市場を押し上げると予想されます。さらに、特許切れの増加やジェネリック医薬品の市場参入により、低価格の感染症治療薬の需要が増加する見込みです。

さらに、これらの感染症の診断と治療に対する保険償還の利用可能性や、これらの疾患の発生率が高い地域における製造業者による医薬品の無料配布は、市場の成長をさらに促進すると予想される要因です。しかし、抗感染症薬の普及率の低さ、多数の偽造薬の入手可能性などが、予測期間中の市場成長を抑制すると予想されます。

2016年は北米市場が最大シェアでした。多数の製造業者の存在、有利な償還シナリオ、医療費の増加が、この地域が最大のシェアを占める主な要因です。しかし、2017年から2025年にかけては、アジア太平洋地域が最も高い成長率を示しそうです。感染症の有病率の高さ、アジア諸国の経済状況の改善、感染症治療の普及に向けた政府のイニシアティブの高まり、資金調達活動の活発化などが、予測期間中にこの地域が最も高い成長率を示す要因となっています。

感染症治療薬市場レポートハイライト

- HIV分野は2022年に31.6%の最大売上シェアを獲得しました。HIVの有病率の増加、HIV感染患者に対する資金援助活動の活発化、アフリカ諸国におけるHIV自己検査キットの無料供給の増加、世界中で啓発キャンペーンが行われていることなどが、このセグメントが最大のシェアを占めている主な要因です。

- HPV分野は、予測期間中にCAGR 8.1%と最も速い成長が見込まれています。成長の主な要因としては、HPVの有病率の増加、この感染症の治療に使用される薬剤の低価格化などが挙げられます。

- 病院セグメントは2022年に54.5%の最大の売上シェアを占めました。感染症を報告する緊急の病院受診件数の増加が、市場の大きな成長要因となっています。

- 北米は2022年に39.9%の最大収益シェアを占めました。このような疾患の有病率の増加と有利な償還シナリオは、この地域の感染症治療薬の需要を促進すると思われる主な要因です。

第1章 調査方法・範囲
第2章 エグゼクティブサマリー
第3章 世界の感染症治療薬市場変数・傾向・範囲
第4章 世界の感染症治療薬市場：疾患種類別予測・傾向分析
第5章 世界の感染症治療薬市場：エンドユーザー別予測・傾向分析
第6章 世界の感染症治療薬市場：地域別予測・傾向分析
第7章 競争状況

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Disease Type
1.1.2. End use
1.1.3. Regional scope
1.1.4. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Disease Type outlook
2.2.2. End use outlook
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Infectious Disease Therapeutics Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. Infectious Disease Therapeutics Market Analysis Tools
3.4.1. Industry Analysis – Porter’s
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape
Chapter 4. Infectious Disease Therapeutics: Disease Type Estimates & Trend Analysis
4.1. Infectious Disease Therapeutics Market: Key Takeaways
4.2. Infectious Disease Therapeutics Market: Movement & Market Share Analysis, 2022 & 2030
4.3. HIV
4.3.1. HIV market estimates and forecasts, 2018 to 2030, (USD Billion)
4.4. Hepatitis
4.4.1. Hepatitis market estimates and forecasts, 2018 to 2030, (USD Billion)
4.5. Influenza
4.5.1. Influenza market estimates and forecasts, 2018 to 2030, (USD Billion)
4.6. TB
4.6.1. TB market estimates and forecasts, 2018 to 2030, (USD Billion)
4.7. Malaria
4.7.1. Malaria market estimates and forecasts, 2018 to 2030, (USD Billion)
4.8. HPV
4.8.1. HPV market estimates and forecasts, 2018 to 2030, (USD Billion)
Chapter 5. Infectious Disease Therapeutics: End Use Estimates & Trend Analysis
5.1. Infectious Disease Therapeutics Market: Key Takeaways
5.2. Infectious Disease Therapeutics Market: Movement & Market Share Analysis, 2022 & 2030
5.3. Hospitals
5.3.1. Hospitals market estimates and forecasts, 2018 to 2030, (USD Billion)
5.4. Clinics
5.4.1. Clinic market estimates and forecasts, 2018 to 2030, (USD Billion)
5.5. Others
5.5.1. Other market estimates and forecasts, 2018 to 2030, (USD Billion)
Chapter 6. Infectious Disease Therapeutics Market: Regional Estimates & Trend Analysis
6.1. Regional Outlook
6.2. Infectious Disease Therapeutics Market by Region: Key Takeaways
6.3. North America
6.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
6.3.2. U.S.
6.3.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
6.3.3. Canada
6.3.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
6.4. Europe
6.4.1. UK
6.4.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
6.4.2. Germany
6.4.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
6.4.3. France
6.4.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
6.4.4. Italy
6.4.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
6.4.5. Spain
6.4.5.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
6.4.6. Denmark
6.4.6.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
6.4.7. Sweden
6.4.7.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
6.4.8. Norway
6.4.8.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
6.5. Asia Pacific
6.5.1. Japan
6.5.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
6.5.2. China
6.5.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
6.5.3. India
6.5.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
6.5.4. Australia
6.5.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
6.5.5. Thailand
6.5.5.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
6.5.6. South Korea
6.5.6.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
6.6. Latin America
6.6.1. Brazil
6.6.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
6.6.2. Mexico
6.6.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
6.6.3. Argentina
6.6.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
6.7. MEA
6.7.1. South Africa
6.7.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
6.7.2. Saudi Arabia
6.7.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
6.7.3. UAE
6.7.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
6.7.4. Kuwait
6.7.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.2.1. Novartis AG
7.2.1.1. Company overview
7.2.1.2. Financial performance
7.2.1.3. Product benchmarking
7.2.1.4. Strategic initiatives
7.2.2. Gilead
7.2.2.1. Company overview
7.2.2.2. Financial performance
7.2.2.3. Product benchmarking
7.2.2.4. Strategic initiatives
7.2.3. GlaxoSmithKline plc
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Product benchmarking
7.2.3.4. Strategic initiatives
7.2.4. Janssen Pharmaceutical, Inc.
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. F. Hoffmann-La Roche Ltd.
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives
7.2.6. BioCryst Pharmaceuticals, Inc.
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Product benchmarking
7.2.6.4. Strategic initiatives
7.2.7. Merck & Co., Inc.
7.2.7.1. Company overview
7.2.7.2. Financial performance
7.2.7.3. Product benchmarking
7.2.7.4. Strategic initiatives
7.2.8. Boehringer Ingelheim GmbH
7.2.8.1. Company overview
7.2.8.2. Financial performance
7.2.8.3. Product benchmarking
7.2.8.4. Strategic initiatives

List of Tables

Table 1 List of Abbreviation
Table 2 North America infectious disease therapeutics market, by disease type, 2018 - 2030 (USD Billion)
Table 3 North America infectious disease therapeutics market, by end use, 2018 - 2030 (USD Billion)
Table 4 North America infectious disease therapeutics market, by region, 2018 - 2030 (USD Billion)
Table 5 U.S. infectious disease therapeutics market, by disease type, 2018 - 2030 (USD Billion)
Table 6 U.S. infectious disease therapeutics market, by end use, 2018 - 2030 (USD Billion)
Table 7 Canada infectious disease therapeutics market, by disease type, 2018 - 2030 (USD Billion)
Table 8 Canada infectious disease therapeutics market, by end use, 2018 - 2030 (USD Billion)
Table 9 Europe infectious disease therapeutics market, by disease type, 2018 - 2030 (USD Billion)
Table 10 Europe infectious disease therapeutics market, by end use, 2018 - 2030 (USD Billion)
Table 11 Europe infectious disease therapeutics market, by region, 2018 - 2030 (USD Billion)
Table 12 Germany infectious disease therapeutics market, by disease type, 2018 - 2030 (USD Billion)
Table 13 Germany infectious disease therapeutics market, by end use, 2018 - 2030 (USD Billion)
Table 14 UK infectious disease therapeutics market, by disease type, 2018 - 2030 (USD Billion)
Table 15 UK infectious disease therapeutics market, by end use, 2018 - 2030 (USD Billion)
Table 16 France infectious disease therapeutics market, by disease type, 2018 - 2030 (USD Billion)
Table 17 France infectious disease therapeutics market, by end use, 2018 - 2030 (USD Billion)
Table 18 Italy infectious disease therapeutics market, by disease type, 2018 - 2030 (USD Billion)
Table 19 Italy infectious disease therapeutics market, by end use, 2018 - 2030 (USD Billion)
Table 20 Spain infectious disease therapeutics market, by disease type, 2018 - 2030 (USD Billion)
Table 21 Spain infectious disease therapeutics market, by end use, 2018 - 2030 (USD Billion)
Table 22 Denmark infectious disease therapeutics market, by disease type, 2018 - 2030 (USD Billion)
Table 23 Denmark infectious disease therapeutics market, by end use, 2018 - 2030 (USD Billion)
Table 24 Sweden infectious disease therapeutics market, by disease type, 2018 - 2030 (USD Billion)
Table 25 Sweden infectious disease therapeutics market, by end use, 2018 - 2030 (USD Billion)
Table 26 Norway infectious disease therapeutics market, by disease type, 2018 - 2030 (USD Billion)
Table 27 Norway infectious disease therapeutics market, by end use, 2018 - 2030 (USD Billion)
Table 28 Asia Pacific infectious disease therapeutics market, by disease type, 2018 - 2030 (USD Billion)
Table 29 Asia Pacific infectious disease therapeutics market, by end use, 2018 - 2030 (USD Billion)
Table 30 Asia Pacific infectious disease therapeutics market, by region, 2018 - 2030 (USD Billion)
Table 31 Japan infectious disease therapeutics market, by disease type, 2018 - 2030 (USD Billion)
Table 32 Japan infectious disease therapeutics market, by end use, 2018 - 2030 (USD Billion)
Table 33 China infectious disease therapeutics market, by disease type, 2018 - 2030 (USD Billion)
Table 34 China infectious disease therapeutics market, by end use, 2018 - 2030 (USD Billion)
Table 35 India infectious disease therapeutics market, by disease type, 2018 - 2030 (USD Billion)
Table 36 India infectious disease therapeutics market, by end use, 2018 – 2030 (USD Billion)
Table 37 Australia infectious disease therapeutics market, by disease type, 2018 - 2030 (USD Billion)
Table 38 Australia infectious disease therapeutics market, by end use, 2018 - 2030 (USD Billion)
Table 39 Thailand infectious disease therapeutics market, by disease type, 2018 - 2030 (USD Billion)
Table 40 Thailand infectious disease therapeutics market, by end use, 2018 - 2030 (USD Billion)
Table 41 South Korea infectious disease therapeutics market, by disease type, 2018 - 2030 (USD Billion)
Table 42 South Korea infectious disease therapeutics market, by end use, 2018 - 2030 (USD Billion)
Table 43 Latin America infectious disease therapeutics market, by disease type, 2018 - 2030 (USD Billion)
Table 44 Latin America infectious disease therapeutics market, by end use, 2018 - 2030 (USD Billion)
Table 45 Latin America infectious disease therapeutics market, by region, 2018 - 2030 (USD Billion)
Table 46 Brazil infectious disease therapeutics market, by disease type, 2018 - 2030 (USD Billion)
Table 47 Brazil infectious disease therapeutics market, by end use, 2018 - 2030 (USD Billion)
Table 48 Mexico infectious disease therapeutics market, by disease type, 2018 - 2030 (USD Billion)
Table 49 Mexico infectious disease therapeutics market, by end use, 2018 - 2030 (USD Billion)
Table 50 Argentina infectious disease therapeutics market, by disease type, 2018 - 2030 (USD Billion)
Table 51 Argentina infectious disease therapeutics market, by end use, 2018 - 2030 (USD Billion)
Table 52 Middle East and Africa infectious disease therapeutics market, by disease type, 2018 - 2030 (USD Billion)
Table 53 Middle East and Africa infectious disease therapeutics market, by end use, 2018 - 2030 (USD Billion)
Table 54 Middle East and Africa infectious disease therapeutics market, by region, 2018 - 2030 (USD Billion)
Table 55 South Africa infectious disease therapeutics market, by disease type, 2018 - 2030 (USD Billion)
Table 56 South Africa infectious disease therapeutics market, by end use, 2018 - 2030 (USD Billion)
Table 57 Saudi Arabia infectious disease therapeutics market, by disease type, 2018 - 2030 (USD Billion)
Table 58 Saudi Arabia infectious disease therapeutics market, by end use, 2018 - 2030 (USD Billion)
Table 59 UAE infectious disease therapeutics market, by disease type, 2018 - 2030 (USD Billion)
Table 60 UAE infectious disease therapeutics market, by end use, 2018 - 2030 (USD Billion)
Table 61 Kuwait infectious disease therapeutics market, by disease type, 2018 - 2030 (USD Billion)
Table 62 Kuwait infectious disease therapeutics market, by end use, 2018 - 2030 (USD Billion)

List of Figures

Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 QFD modeling for market share assessment
Fig. 6 Market formulation & validation
Fig. 7 Infectious disease therapeutics: Market outlook
Fig. 8 Infectious disease therapeutics: Competitive insights
Fig. 9 Parent market outlook
Fig. 10 Related/ancillary market outlook
Fig. 11 Penetration and growth prospect mapping
Fig. 12 Industry value chain analysis
Fig. 13 Infectious disease therapeutics market driver impact
Fig. 14 Infectious disease therapeutics market restraint impact
Fig. 15 Infectious disease therapeutics market strategic initiatives analysis
Fig. 16 Infectious disease therapeutics market: Disease type movement analysis
Fig. 17 Infectious disease therapeutics market: Disease type outlook and key takeaways
Fig. 18 HIV market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 19 Hepatitis market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 20 Influenza market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 21 TB market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 22 Malaria market estimates and forecasts, 2018 - 2030
Fig. 23 HPV market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 24 Infectious disease therapeutics market: End Use movement analysis
Fig. 25 Infectious disease therapeutics market: End Use outlook and key takeaways
Fig. 26 Hospitals market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 27 Clinics market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 28 Others market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 29 Global infectious disease therapeutics market: Regional movement analysis
Fig. 30 Global infectious disease therapeutics market: Regional outlook and key takeaways
Fig. 31 North America market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 32 U.S. market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 33 Canada market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 34 Europe market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 35 UK market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 36 Germany market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 37 France market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 38 Italy market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 39 Spain market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 40 Denmark market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 41 Sweden market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 42 Norway market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 43 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 44 Japan market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 45 China market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 46 India market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 47 Australia market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 48 Thailand market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 49 South Korea market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 50 Latin America market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 51 Brazil market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 52 Mexico market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 53 Argentina market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 54 Middle East and Africa. market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 55 South Africa market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 56 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 57 UAE market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 58 Kuwait market estimates and forecasts, 2018 - 2030 (USD Billion)

★調査レポート[世界の感染症治療薬市場2023-2030：疾患種類別（HIV、肝炎、インフルエンザ、結核、マラリア、HPV）、エンドユーザー別（病院、診療所）、地域別] (コード：GRV23NOV149)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の感染症治療薬市場2023-2030：疾患種類別（HIV、肝炎、インフルエンザ、結核、マラリア、HPV）、エンドユーザー別（病院、診療所）、地域別]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界の腫瘍コンパニオン診断市場（2023-2030）：製品・サービス別、技術別（IHC、NGS）、疾患種類別（乳がん、白血病）、エンドユーザー別、地域別
  • 世界の難聴疾患治療市場2023-2030：製品別（機器、医薬品）、疾患種類別（伝導性難聴、感音性難聴）、エンドユーザー別（病院、耳鼻科診療所）
  • 世界の網膜静脈閉塞症治療市場（2023-2030）：エンドユーザー別（小売薬局、病院・診療所）、疾患種類別（CRVO、BRVO）、治療薬別（抗VEGF薬、副腎皮質ステロイド薬）、地域別
  • 世界の腸疾患検査市場2023-2030：疾患種類別（細菌性腸疾患、ウイルス性腸疾患、寄生性腸疾患）、地域別
  • 世界の呼吸器疾患ワクチン市場2023-2030：種類別（ウイルス、細菌、混合）、年齢層別、感染症別（新型コロナウイルス感染症、インフルエンザ）、流通チャネル別、地域別
  • 世界の遺伝性検査市場2023-2030：疾患種類別（遺伝性がん検査、遺伝性非がん検査）、技術別（細胞遺伝学、生化学、分子検査）、地域別
  • 世界の結核治療薬市場2023-2030：疾患種類別（活動性結核、潜在性結核）、治療法別、投与経路別、剤形別、流通チャネル別、地域別
  • 世界のデュピュイトラン病市場2023-2030：種類別（診断、治療）、疾患種類別（タイプ I、タイプ II）、最終用途別（病院、診療所）、地域別（ヨーロッパ、アジア太平洋）

    • ◆H&Iグローバルリサーチのお客様（例）◆